Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
P/B ratio for Corvus Pharmaceuticals, Inc. (CRVS)
P/B ratio as of 2023: 2.18
According to Corvus Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.18. At the end of 2022 the company had a P/B ratio of 0.71.
P/B ratio history for Corvus Pharmaceuticals, Inc. from 2014 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.18 |
| 2022 | 0.71 |
| 2021 | 1.04 |
| 2020 | 1.45 |
| 2019 | 2.25 |
| 2018 | 0.92 |
| 2017 | 2.50 |
| 2016 | 1.66 |
| 2015 | -9.35 |
| 2014 | -15.24 |